Lamotrigine in multihandicapped therapy-resistant epileptic patients

Area of Science:

• Neurology
• Pharmacology
• Clinical Epilepsy Research

Background:

• Severe, therapy-resistant epilepsy presents significant challenges in management.
• Patients with epilepsy often have multiple comorbidities, complicating treatment decisions.

Purpose of the Study:

• To evaluate the efficacy and tolerability of lamotrigine as an add-on therapy in patients with severe, therapy-resistant epilepsy.
• To identify factors influencing lamotrigine's effectiveness in a specialized patient population.

Main Methods:

• An open, observational, add-on study design was employed.
• 125 resident patients with severe epilepsy and multiple handicaps received titrated doses of lamotrigine.
• Seizure frequency, severity, and psychological status were monitored over a 3-month baseline and 3-month treatment period.

Main Results:

• 71.4% of patients continued lamotrigine treatment long-term (mean 21.9 months).
• The overall responder rate (≥50% seizure reduction) was 28.8%, with higher rates in focal epilepsy (35.6%).
• Lamotrigine was more effective with valproic acid (p < 0.005) and less effective with carbamazepine or phenytoin; valproic acid was the sole predictor of response.
• 53.6% of patients showed overall benefit across efficacy criteria, while 8.8% deteriorated.
• Common adverse effects included ataxia, dizziness, and diplopia.

Conclusions:

• Lamotrigine is an effective and well-tolerated treatment option for this specific group of patients with severe epilepsy.
• Combination therapy with valproic acid significantly enhances lamotrigine's efficacy.
• The study highlights the importance of individualized treatment strategies in complex epilepsy cases.